Quintiles

BMS selects Quintiles as preferred central laboratory provider

Tuesday, April 16, 2013 10:06 AM

Quintiles, a provider of biopharmaceutical development and commercial outsourcing services, has been chosen as a preferred provider by Bristol-Myers Squibb to provide global support for BMS's central lab work, biomarker testing and assay development for the next five years.

More... »

Quintiles digital properties win two Web Marketing Assoc. awards

Thursday, April 4, 2013 08:00 AM

Quintiles, a provider of biopharmaceutical development and commercial outsourcing services, has received further recognition for the company’s digital communications with two “Internet Advertising Competition” (IAC) awards: one for its corporate website, Quintiles.com, and one for its patient education site, ClinicalResearch.com.

More... »

The CenterWatch Monthly, March 2013

Friday, March 1, 2013 08:00 AM

Sites rate the best sponsors 2013

More... »

Quintiles files registration statement for IPO

Friday, February 15, 2013 05:03 PM

Quintiles Transnational Holdings has filed a registration statement with the U.S. Securities and Exchange Commission (SEC) relating to a proposed initial public offering of its common stock.

More... »

Cardiome selects Quintiles to manage global regulatory affairs for Brinavess

Monday, February 11, 2013 10:22 AM

Biopharmaceutical company Cardiome Pharma has selected Quintiles, a global provider of biopharmaceutical services, to provide comprehensive post-marketing lifecycle safety and global regulatory affairs services for Brinavess (vernakalant intravenous). Quintiles will begin providing these services effective immediately as Cardiome continues to prepare for the anticipated transfer of Brinavess from Merck to Cardiome.

More... »

Synteract appoints Kelson as CFO, Doren as vice president of biometrics

Wednesday, January 30, 2013 03:18 PM

Synteract, a full service CRO based in Carlsbad, Calif., has hired new executives to support customers on a global scale. Keith Kelson will serve as chief financial officer and member of its executive council, and Phil Doren has been appointed vice president of biometrics.

More... »

Kareus initiates phase I trial in Alzheimer's disease

Friday, January 4, 2013 02:51 PM

Kareus Therapeutics, a private biotechnology company focused on unmet treatment of age-related and chronic diseases, has initiated a phase I clinical study following the Investigational New Drug (IND) approval from the FDA for the development of KU-046, a first-in-class disease modifying new chemical entity discovered for the treatment of Alzheimer's disease using Kareus' proprietary bioenergetics and KARLECT platforms.

More... »

INC Research strengthens leadership for strategic advisory services unit

Monday, December 10, 2012 01:44 PM

INC Research, a therapeutically focused CRO, has appointed Robert Ryan, PhD, as vice president of regulatory strategy, consulting and submissions. Ryan will provide global leadership to position INC Strategic Advisory Services as a market leader in regulatory consulting and submissions offerings.

More... »

Drug discovery services market to reach $16.6B in 2015

Monday, December 10, 2012 10:09 AM

A new report by visiongain, an independent media company based in London, predicts that the world market for drug discovery outsourcing will reach $16.6 billion in 2015. That revenue forecast and others appear in “DrugDiscovery Outsourcing: World Market 2013-2023,” published in November 2012.

More... »

CRA enters strategic alliance with Quintiles

Tuesday, November 27, 2012 11:42 AM

Tempe, Ariz.-based Clinical Research Advantage (CRA), a community-based network of clinical trial sites, has entered into a strategic agreement  with CRO Quintiles to facilitate a higher level of clinical trial participation with an emphasis on safety, improved study efficiencies and quality data.

More... »